Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103
Chaitra S. Ujjani(Fred Hutch Cancer Center), Bruce D. Cheson(Center for Cancer and Blood Disorders), Sin‐Ho Jung(Duke University), John P. Leonard(New York University), Peter Martin(NewYork–Presbyterian Hospital), Kristie A. Blum(Emory University), Matthew S. Davids(Dana-Farber Cancer Institute), Nancy L. Bartlett(Washington University in St. Louis), Lionel D. Lewis(Dartmouth College), Ellis Levine(University of Maryland, Baltimore), Scott E. Smith(Loyola University Medical Center), Myron S. Czuczman(Roswell Park Comprehensive Cancer Center), Sonali M. Smith(University of Chicago), Steven I. Park(University of North Carolina at Chapel Hill), Brandelyn N. Pitcher(Statistical and Applied Mathematical Sciences Institute)
Cited by 59
Related Papers
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k